Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Functional Improvement of Non-Infarct-Related Coronary Artery Stenosis by Extensive LDL-C Reduction with Evolocumab
2019-002578-29Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary arteriosclerosis comparing Evolocumab arm with Placebo arm (2 arms). Primary endpoint: Change in FFR of non-infarct-related artery lesions. Started Oct 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2019-002578-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002578-29.